Guide Use of Tocilizumab for COVID-19 Based on New Data

March 2021

You’ll hear renewed interest in tocilizumab for COVID-19...based on new data suggesting it reduces mortality in some patients.

IL-6 inhibitors, such as tocilizumab (Actemra), sparked early interest in COVID-19 to block cytokines and reduce inflammation.

But trials haven’t consistently demonstrated a benefit.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote